The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus

Abstract

An international panel of multidisciplinary experts convened to develop recommendations for the management of patients with liver metastases from colorectal cancer (CRC). The aim was to address the main issues facing the CRC hepatobiliary multidisciplinary team (MDT) when managing such patients and to standardize the treatment patients receive in different centers. Based on current evidence, the group agreed on a number of issues including the following: (a) the primary aim of treatment is achieving a long disease-free survival (DFS) interval following resection; (b) assessment of resectability should be performed with high-quality cross-sectional imaging, staging the liver with magnetic resonance imaging and/or abdominal computed tomography (CT), depending on local expertise, staging extrahepatic disease with thoracic and pelvic CT, and, in selected cases, fluorodeoxyglucose positron emission tomography with ultrasound (preferably contrast-enhanced ultrasound) for intraoperative staging; (c) optimal first-line chemotherapy-doublet or triplet chemotherapy regimens combined with targeted therapy-is advisable in potentially resectable patients; (d) in this situation, at least four courses of first-line chemotherapy should be given, with assessment of tumor response every 2 months; (e) response assessed by the Response Evaluation Criteria in Solid Tumors (conventional chemotherapy) or nonsize-based morphological changes (antiangiogenic agents) is clearly correlated with outcome; no imaging technique is currently able to accurately diagnose complete pathological response but high-quality imaging is crucial for patient management; (f) the duration of chemotherapy should be as short as possible and resection achieved as soon as technically possible in the absence of tumor progression; (g) the number of metastases or patient age should not be an absolute contraindication to surgery combined with chemotherapy; (h) for synchronous metastases, it is not advisable to undertake major hepatic surgery during surgery for removal of the primary CRC; the reverse surgical approach (liver first) produces as good an outcome as the conventional approach in selected cases; (i) for patients with resectable liver metastases from CRC, perioperative chemotherapy may be associated with a modestly better DFS outcome; and (j) whether initially resectable or unresectable, cure or at least a long survival duration is possible after complete resection of the metastases, and MDT treatment is essential for improving clinical and survival outcomes. The group proposed a new system to classify initial unresectability based on technical and oncological contraindications.

Conflict of interest statement

Disclosures: René Adam: Merck Serono, Roche, Sanofi-Aventis (CA); Merck Serono, Pfizer, Roche, Sanofi-Aventis (H); Aimery De Gramont: Sanofi (C/A); Roche, Amgen (H); Joan Figueras: Roche, Merck Serono (C/A); Roche, Merck Serono (H); Ashley Guthrie: Bayer Healthcare, Serono Symposia International Foundation (H); Norihiro Kokudo: Dainippon Sumitomo Pharma and Bayer (RF); Evelyne Loyer: Novartis Pharma AG (C/A); Roche (H); Graeme Poston: Merck, Sanofi, Pfizer, Biocompatibles (C/A, H); Philippe Rougier: Merck Serono, Sirtex, Keocyt, Sanofi (C/A); Servier, Roche (RF); Amgen, Merck Serono, Pfizer, Sanofi (participated in presentations); Alberto Sobrero: Amgen, Merck Serono, Roche, Sanofi (C/A); Amgen, Bayer, Roche, Sanofi (H); Josep Tabernero: Amgen, Genentech, Merck Serono, Roche, and Sanofi Aventis (C/A), Amgen, Merck Serono, Roche, Sanofi Aventis (participated in presentations); Catherine Teh: Merck Serono (participated in presentations); Eric Van Cutsem: Roche, Merck Serono, Sanofi, Pfizer (RF); Jean-Nicolas Vauthey: Sanofi-Aventis, Roche (H); Sanofi-Aventis, Roche (RF). The other authors indicated no financial relationships.

Figures

Figure 1.

Overall survival probability in relation to response to preoperative chemotherapy in 4,851 patients undergoing a first resection of colorectal liver metastases from the LiverMetSurvey [78]. Reproduced with permission from http://www.livermetsurvey.org, June 2011.

Figure 2.

Overall survival probability after a first resection for colorectal liver metastases in 14,774 patients from the LiverMetSurvey [78]. Reproduced with permission from http://www.livermetsurvey.org, June 2011.

Figure 3.

Overall survival probability after resection of initially unresectable versus nonresectable liver metastases. Data from 10,940 patients in the LiverMetSurvey [78]. Reproduced with permission from http://www.livermetsurvey.org, June 2011.